Pipeline: CDK7

CDK7

Small Cell Lung Cancer

 

Mode of Action:

Inhibition of CDK7 shuts down super-enhancer-linked oncogenic transcription in MYC-driven cancers. CDK7 acts at a pivotal junction of the cell cycle by phosphorylating RNA polymerase II and promoting general transcription. Inhibition of CDK7 in small cell lung cancer should slow growth and metastasis of the tumors and in combination with chemotherapy, provide tumor shrinkage.

Status

  • Proof of Concept
  • Lead Generation

Click on the image to expand and view description.